Quotient Sciences Quotient Sciences

X

Find the latest Drugs in Development and Pipeline Prospector News of DKSH.

  • Webinars & Exhibitions

PharmaCompass
DKSH
DKSH
Switzerland Flag
Country
Country
Switzerland
Address
Address
Wiesenstrasse 8, P.O. Box 888 Zurich, Zurich 8034, CH
Telephone
Telephone
+49 4037473411
Contact Info
Others

left grey arrow
right gray arrow

Details:

Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.


Lead Product(s): Bentonite,Mono Propylene Glycol,Citric Acid

Therapeutic Area: Immunology Product Name: Bentrio

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Nuance Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership November 28, 2022

Details:

Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.


Lead Product(s): Eperisone Hydrochloride

Therapeutic Area: Neurology Product Name: Myonal

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Eisai

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 07, 2022

Details:

The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.


Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: LP0133

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Leo Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 29, 2022

Details:

The biosimilars planned under this agreement include biosimilar of Prolia® (denosumab, AVT03), Xgeva® (denosumab), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.


Lead Product(s): Denosumab

Therapeutic Area: Musculoskeletal Product Name: AVT03

Highest Development Status: Phase IIIProduct Type: Large molecule

Recipient: Lupin Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement September 07, 2022

Details:

Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Large molecule

Recipient: Alvotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 24, 2020

Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY